Gossamer Bio, Inc. is testing its inhaled kinase inhibitor seralutinib in a Phase III clinical trial as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH), but has its eyes on the larger, less crowded market of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Now, after signing a deal with Chiesi Farmaceutici S.p.A., Gossamer has the resources to begin a Phase III trial in PH-ILD at least four years sooner than planned.
Key Takeaways
-
Gossamer, down to its last drug candidate, sees a path to blockbuster status with seralutinib and can expand from PAH into a second indication of PH-ILD faster with new partner Chiesi.
San Diego-based Gossamer and the Italian respiratory and rare disease specialist Chiesi announced their global collaboration and license agreement on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
